Skip Navigation

A Phase I Study Evaluating SC262, a Hypoimmune, Allogeneic CD22-directed CAR T Cell Therapy, in Relapsed and/or Refractory Non-Hodgkin?s Lymphoma VIVID

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT06285422

Study #:
STUDY00160465

Start Date:
Sep 20, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06285422

View Complete Trial Details & Eligibility at ClinicalTrials.gov